These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 1489561)

  • 1. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Demicheli V; Jefferson TO
    J Public Health Med; 1992 Dec; 14(4):367-75. PubMed ID: 1489561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-benefit analysis of the Polish hepatitis B prevention programme.
    Wiewióra-Pilecka D
    Vaccine; 2000 Feb; 18 Suppl 1():S52-4. PubMed ID: 10683548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic analysis of the first 20 years of universal hepatitis B vaccination program in Italy: an a posteriori evaluation and forecast of future benefits.
    Boccalini S; Taddei C; Ceccherini V; Bechini A; Levi M; Bartolozzi D; Bonanni P
    Hum Vaccin Immunother; 2013 May; 9(5):1119-28. PubMed ID: 23376840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis.
    Bloom BS; Hillman AL; Fendrick AM; Schwartz JS
    Ann Intern Med; 1993 Feb; 118(4):298-306. PubMed ID: 8420448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness and cost benefit of viral hepatitis B vaccination in the Slovak Republic.
    Hudecková H; Straka S; Szilágyiová M; Avdicová M; Rusnáková S
    Cent Eur J Public Health; 2002 Dec; 10(4):146-8. PubMed ID: 12528387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Economic evaluation of various hepatitis B vaccination strategies in children and adolescents].
    Szucs TD; Smala A; Berger K; Windorfer A
    Med Klin (Munich); 1998 Aug; 93(8):468-77. PubMed ID: 9747102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness.
    Da Villa G; Sepe A
    Vaccine; 1999 Mar; 17(13-14):1734-8. PubMed ID: 10194831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Economic evaluation on strategy for preventing mother-to-child transmission of hepatitis B in Zhejiang Province].
    Zeng YB; Luo ML; He HQ; Deng X; Xie SY; Fang Y
    Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):706-712. PubMed ID: 31288342
    [No Abstract]   [Full Text] [Related]  

  • 9. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An economic evaluation of universal vaccination against hepatitis B virus.
    Fenn P; Gray A; McGuire A
    J Infect; 1996 May; 32(3):197-204. PubMed ID: 8793708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cost-effectiveness analysis of different alternatives of universal vaccination against hepatitis B in the region of Murcia].
    Guillén Grima F; Espín Ríos MI
    Med Clin (Barc); 1995 Feb; 104(4):130-6. PubMed ID: 7898156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-benefit analysis of the introduction of mass vaccination against hepatitis B in Italy.
    Johnstone T
    J Public Health Med; 1993 Sep; 15(3):289-90. PubMed ID: 8251212
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale for the infant and adolescent vaccination programmes in Italy.
    Da Villa G
    Vaccine; 2000 Feb; 18 Suppl 1():S31-4. PubMed ID: 10683541
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Economic evaluation of various hepatitis B vaccination Strategies in Switzerland].
    Zurn P; Danthine JP
    Soz Praventivmed; 1998; 43 Suppl 1():S61-4, S134-7. PubMed ID: 9833269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An economic analysis of adult hepatitis B vaccination in China.
    Zheng H; Wang FZ; Zhang GM; Cui FQ; Wu ZH; Miao N; Sun XJ; Liang XF; Li L
    Vaccine; 2015 Nov; 33(48):6831-9. PubMed ID: 26384449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients.
    Oddone EZ; Cowper PA; Hamilton JD; Feussner JR
    Health Serv Res; 1993 Apr; 28(1):97-121. PubMed ID: 8463111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probabilistic cost-effectiveness analysis of the long-term effect of universal hepatitis B vaccination: an experience from Taiwan with high hepatitis B virus infection and Hepatitis B e Antigen positive prevalence.
    Hung HF; Chen TH
    Vaccine; 2009 Nov; 27(48):6770-6. PubMed ID: 19735755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience.
    Germinario C; Lopalco PL; Chirona M; Da Villa G
    Vaccine; 2000 Feb; 18 Suppl 1():S83-5. PubMed ID: 10683558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of infant and adolescent hepatitis B vaccination in the UK.
    Siddiqui MR; Gay N; Edmunds WJ; Ramsay M
    Vaccine; 2011 Jan; 29(3):466-75. PubMed ID: 21073988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.